# EDGAR Filing Document

**Accession Number:** 0001534248
**File Stem:** 0001178913-26-002423
**Filing Date:** 2026-5
**Character Count:** 4164
**Document Hash:** 4177b4e8b6a15d193c734c111e15b0aa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-002423.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001178913-26-002423

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260506

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chemomab Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001534248
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813676773
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38807
- **FILM NUMBER:** 26949555

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972-77-331-0156

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anchiano Therapeutics Ltd.
- **DATE OF NAME CHANGE:** 20180906

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioCancell Ltd.
- **DATE OF NAME CHANGE:** 20111104

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION** **<br> Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2026

Commission File Number 001-38807

**CHEMOMAB THERAPEUTICS LTD.**<br> (Translation of registrant's name into English)

**10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**EXPLANATORY NOTE**

Chemomab Therapeutics Ltd. (the "Company") hereby furnishes the results of its annual general shareholders meeting (the "Meeting"), which was scheduled for April 28, 2026 and adjourned to May 5, 2026, at 4:30 p.m. (Israel time), at Meitar \| Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel.

At the Meeting, the Company's shareholders voted upon and approved, by the requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association (the "Articles"), the following proposals: (i) the re-election of each of Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors, (ii) the approval of the compensation policy for office holders and directors, (iii) the approval of an increase of the Company's authorized share capital and to amend the Company's Articles accordingly, and (iv) the re-appointment of Somekh Chaikin, a member firm of KPMG international, as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2026; all in accordance with the Company's proxy statement related to the Meeting, which was attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on March 20, 2026.

This Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File No. [333-275002](https://www.sec.gov/Archives/edgar/data/1534248/000117891323003439/zk2330437.htm) and [333-281750](https://www.sec.gov/Archives/edgar/data/1534248/000117891324002748/zk2431902.htm)) and Form S-8 (File No. [333-259489](https://www.sec.gov/Archives/edgar/data/1534248/000117891321002984/zk2126574.htm) and No. [333-266868](https://www.sec.gov/Archives/edgar/data/1534248/000117891322003108/zk2228346.htm)).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CHEMOMAB THERAPEUTICS LTD.** | **CHEMOMAB THERAPEUTICS LTD.** |
| Date: May 6, 2026 | By: | /s/ Sigal Fattal |
|  |  | Sigal Fattal |
|  |  | Chief Financial Officer |

---